COMMUNIQUÉS West-GlobeNewswire

DBV Technologies to Attend Upcoming Investor Conferences
03/06/2019
Montrouge, France, June 3, 2019 DBV Technologies to Attend Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, [...]
DBV Technologies invitée à présenter lors de prochaines conférences Investisseurs
03/06/2019
Montrouge, France, le 3 juin (7H30 CET), 2019 DBV Technologies invitée à présenter lors de prochaines conférences Investisseurs DBV Technologies (Euronext: DBV – ISIN : FR0010417345 - Nasdaq Stock Market : DBVT), une [...]
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
03/06/2019
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon- [...]
Basilea reports publication of clinical data for anticancer drug candidates BAL101553 in glioblastoma and derazantinib in intrahepatic cholangiocarcinoma at ASCO meeting
03/06/2019
Basel, Switzerland, June 3, 2019 – Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today the phase 1 data from an ongoing study with the oral formulation of its novel tumor checkpoint controller, BAL101553, in brain [...]
Xolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
03/06/2019
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate response to intranasal [...]
Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
03/06/2019
Roche presents data from across its breast cancer portfolio at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting Roche data from 17 breast cancer abstracts presented at this year’s meeting An overall [...]
Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas
02/06/2019
ADU-S100 (MIW815) + spartalizumab combination data demonstrated antitumor activity in anti-PD-1-naïve triple-negative breast cancer (TNBC) and previously immunotherapy-treated melanoma As of the April 5, 2019 data cut- [...]
Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma
02/06/2019
Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma News Summary: Isatuximab, an investigational anti- [...]
L'essai de phase III de l'isatuximab combiné au pomalidomide et à la dexaméthasone a permis d'obtenir une réduction de 40 % du risque de progression ou de décès chez des patients atteint d'un myélo...
02/06/2019
L'essai de phase III de l'isatuximab combiné au pomalidomide et à la dexaméthasone a permis d'obtenir une réduction de 40 % du risque de progression ou de décès chez des patients atteint d'un myélome multiple [...]
Corvus Pharmaceuticals Presents Initial CPI-006 Phase 1/1b Clinical Data at 2019 ASCO Annual Meeting
02/06/2019
Clinical and laboratory results support a new immuno-oncology approach with CPI-006 via activation of immune cells and the inhibition of adenosine production Initial Results demonstrated dose-dependent disease control [...]
Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting
02/06/2019
– Controlled IL-12 evaluated as monotherapy in an expanded number of patients confirmed rapid and safe activation of immune system – –Controlled IL-12 can be combined with increasing doses of a PD-1 inhibitor and immune [...]
BRACAnalysis CDx® Companion Diagnostic Test Identifies Patients with Metastatic Pancreatic Cancer Who Benefited from Treatment with Lynparza® (olaparib)
02/06/2019
NCCN Guidelines Recommend Genetic Testing for All Patients with Pancreatic Cancer SALT LAKE CITY, June 02, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics , Inc. (NASDAQ: MYGN), a leader in personalized medicine, today [...]
Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases
02/06/2019
Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases Data will be presented [...]
Les résultats financiers du premier trimestre 2019 de Emerald Health Therapeutics démontrent une croissance continue des ventes
02/06/2019
Les ventes de Emerald augmentent de 131 % d'un trimestre à l'autre VANCOUVER, Colombie-Britannique, 02 juin 2019 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (« Emerald ») (TSXV: EMH; OTCQX: EMHTF) a présenté [...]
G1 Therapeutics Presents Additional Phase 2 Data on Trilaciclib in Small Cell Lung Cancer at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
01/06/2019
RESEARCH TRIANGLE PARK, N.C., June 01, 2019 (GLOBE NEWSWIRE) -- - New patient-reported outcomes data shows trilaciclib improves chemotherapy experience for patients - G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical- [...]
Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma
01/06/2019
--Evaluation of biomarkers for patient selection to be incorporated into expanded development program-- HAMPTON, N.J., June 01, 2019 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today presented results [...]
Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients with Head and Neck Squamous Cell Carcinoma at the 2019 ASCO Annual Meeting
01/06/2019
24% overall response rate in ITT population Responses were observed in SD-101 injected and non-injected lesions The combination of SD-101 and pembrolizumab was well-tolerated BERKELEY, Calif., June 01, 2019 (GLOBE [...]
Merus annonce ses résultats financiers pour le premier trimestre 2019 et fait le point sur ses activités
01/06/2019
UTRECHT, Pays-Bas, 01 juin 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq : MRUS) (« Merus », « nous », « notre » ou la « Société »), société spécialisée en immuno-oncologie de stade clinique qui développe Biclonics®, un [...]
XBiotech annonce la tarification de son offre publique pour l'émission d'actions ordinaires
01/06/2019
AUSTIN, Texas, 01 juin 2019 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a annoncé aujourd'hui la tarification d'une offre publique de souscription portant sur 4 848 485 de ses actions ordinaires à un prix public [...]

Pages